Last reviewed · How we verify
NCT07391397: APEX
Assessing PFAS Exposure (APEX) for Better Health
NA trial testing Blood Test and Report Back in Environmental Health Effects in 110 participants. Participants enrolled and being followed up; not accepting new ones.
31 January 2026
Quick facts
| Lead sponsor | Million Marker Wellness, Inc. |
|---|---|
| Phase | NA |
| Status | Active, enrolled |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | prevention |
| Enrollment | 110 |
| Start date | 1 September 2025 |
| Primary completion | 31 January 2026 |
| Estimated completion | 28 February 2026 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Blood Test and Report Back
Conditions studied
- Environmental Health Effects — all drugs for Environmental Health Effects →
Sponsor
Million Marker Wellness, Inc. — full company profile →
Who can join
18 and older, any sex, with Environmental Health Effects. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this observational study is to determine whether a personalized PFAS (per- and polyfluoroalkyl substances) blood test and educational report-back can improve environmental health literacy (EHL), empower exposure reduction behaviors, and promote cardiovascular wellness among rural adults. The main questions it aims to answer are: Does receiving a personalized PFAS test result and educational report-back increase environmental health literacy among rural participants and healthcare providers? Does increased EHL lead to greater readiness and actions to reduce PFAS exposure and improve wellness outcomes (e.g., reduced stress, improved sleep, increased sense of control) Researchers will compare changes from pre- to post-intervention among participants who receive the personalized PFAS report-back to see if there are measurable improvements in knowledge, behavior, and wellbeing. Participants will: Provide a mail-in blood spot sample for PFAS testing using a validated laboratory method (Relentless Health). Complete online surveys before and after receiving results to assess PFAS knowledge, exposure behaviors, and wellness outcomes. Receive a personalized PFAS report-back summarizing individual results, exposure sources, and tailored strategies for exposure reduction. Participate in focus groups or interviews (subset only) to provide feedback on report clarity, usability, and communication preferences. This study focuses on rural adult residents of Nevada, including underserved populations who may face limited access to PFAS testing or environmental health education. Insights from this Phase I project will guide a future randomized controlled trial evaluating the intervention's broader impact on cardiovascular health and rural health equity.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07391397
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other Million Marker Wellness, Inc. trials
Trials by the same sponsor.
- NCT07461857 — Minority-focused Environmental Health Education and Tracking (MEET) Pilot Study · NA · completed
- NCT06450951 — A Personalized Biomonitoring and Report-back Intervention to Reduce Exposure to Endocrine Disrupting Chemicals · NA · active not recruiting
- NCT05780047 — Personalized Mobile Intervention to Reduce Exposure to Endocrine Disrupting Chemicals in Adults of Child-Bearing Age · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07391397 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Million Marker Wellness, Inc.
- Last refreshed: 5 February 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07391397.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing